Equities Analysts Offer Predictions for Bausch Health Companies Inc’s Q2 2019 Earnings (BHC)

Bausch Health Companies Inc (TSE:BHC) – Stock analysts at Piper Jaffray Companies raised their Q2 2019 earnings per share estimates for shares of Bausch Health Companies in a research note issued to investors on Monday, May 6th, Zacks Investment Research reports. Piper Jaffray Companies analyst D. Amsellem now forecasts that the company will post earnings of $1.39 per share for the quarter, up from their prior forecast of $1.32. Piper Jaffray Companies also issued estimates for Bausch Health Companies’ Q3 2019 earnings at $1.37 EPS, Q4 2019 earnings at $1.48 EPS, FY2019 earnings at $5.58 EPS, Q1 2020 earnings at $1.18 EPS, Q2 2020 earnings at $1.55 EPS, Q3 2020 earnings at $1.57 EPS, Q4 2020 earnings at $1.70 EPS, FY2020 earnings at $6.00 EPS, FY2022 earnings at $7.33 EPS and FY2023 earnings at $7.94 EPS.

Bausch Health Companies (TSE:BHC) last released its earnings results on Monday, May 6th. The company reported C$1.37 EPS for the quarter, topping the consensus estimate of C$1.18 by C$0.19. The business had revenue of C$2.68 billion for the quarter, compared to analyst estimates of C$2.70 billion.

Separately, BMO Capital Markets cut their price target on Bausch Health Companies from C$26.00 to C$25.00 in a report on Thursday, February 21st.

TSE:BHC traded down C$0.91 on Tuesday, hitting C$28.06. The stock had a trading volume of 1,036,510 shares, compared to its average volume of 859,763. The firm has a market cap of $10.19 billion and a P/E ratio of -6.09. The company has a debt-to-equity ratio of 878.70, a quick ratio of 0.65 and a current ratio of 1.09. Bausch Health Companies has a 52 week low of C$23.60 and a 52 week high of C$36.52.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Story: Understanding debt-to-equity ratio in fundamental analysis

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (TSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.